Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Conformationally Constrained Cinnolinone Nucleoside Analogues as Siderophore Biosynthesis Inhibitors for Tuberculosis.

Dawadi S, Boshoff HIM, Park SW, Schnappinger D, Aldrich CC.

ACS Med Chem Lett. 2018 Mar 16;9(4):386-391. doi: 10.1021/acsmedchemlett.8b00090. eCollection 2018 Apr 12.

PMID:
29670706
2.

Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.

van der Laan LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, Wiesner L, de Kock M, Winckler J, Norman J, McIlleron H, Denti P, Hesseling AC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e00420-17. doi: 10.1128/AAC.00420-17. Print 2018 Feb.

PMID:
29133558
3.

Autophagy induction targeting mTORC1 enhances Mycobacterium tuberculosis replication in HIV co-infected human macrophages.

Andersson AM, Andersson B, Lorell C, Raffetseder J, Larsson M, Blomgran R.

Sci Rep. 2016 Jun 15;6:28171. doi: 10.1038/srep28171.

4.

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

Hennig S, Svensson EM, Niebecker R, Fourie PB, Weiner MH, Bonora S, Peloquin CA, Gallicano K, Flexner C, Pym A, Vis P, Olliaro PL, McIlleron H, Karlsson MO.

J Antimicrob Chemother. 2016 May;71(5):1330-40. doi: 10.1093/jac/dkv470. Epub 2016 Jan 31.

5.

Early versus Delayed Antiretroviral Therapy for HIV and Tuberculosis Co-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Yan S, Chen L, Wu W, Fu Z, Zhang H, Li Z, Fu C, Mou J, Xue J, Hu Y.

PLoS One. 2015 May 22;10(5):e0127645. doi: 10.1371/journal.pone.0127645. eCollection 2015. Review.

6.

The role of delamanid in the treatment of drug-resistant tuberculosis.

Lewis JM, Sloan DJ.

Ther Clin Risk Manag. 2015 May 13;11:779-91. doi: 10.2147/TCRM.S71076. eCollection 2015. Review.

7.

Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge.

Bisson GP, Zetola N, Collman RG.

Curr HIV/AIDS Rep. 2015 Mar;12(1):107-16. doi: 10.1007/s11904-015-0256-x. Review.

8.

Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR.

Antimicrob Agents Chemother. 2014 Oct;58(10):6242-50. doi: 10.1128/AAC.03073-14. Epub 2014 Aug 11.

9.

Delayed antiretroviral therapy despite integrated treatment for tuberculosis and HIV infection.

Patel MR, Nana M, Yotebieng M, Tabala M, Behets F, Van Rie A.

Int J Tuberc Lung Dis. 2014 Jun;18(6):694-9. doi: 10.5588/ijtld.13.0807.

10.

Cyto-genotoxicity Assessment of Potential Anti-tubercular Drug Candidate Molecule-trans-cyclohexane-1, 4-diamine Derivative-9u in Human Lung Epithelial Cells A549.

Kapoor E, Tripathi V, Kumar V, Juyal V, Bhagat S, Ram V.

Toxicol Int. 2014 Jan;21(1):69-77. doi: 10.4103/0971-6580.128800.

11.

High rates of tuberculosis in patients accessing HAART in rural South Africa.

Naidoo K, Karim QA, Bhushan A, Naidoo K, Yende-Zuma N, McHunu PK, Frohlich J, Karim F, Upfold M, Kocheleff P, Abdool Karim SS.

J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):438-46. doi: 10.1097/QAI.0000000000000060.

12.

Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay.

Martinez JP, Hinkelmann B, Fleta-Soriano E, Steinmetz H, Jansen R, Diez J, Frank R, Sasse F, Meyerhans A.

Microb Cell Fact. 2013 Sep 24;12:85. doi: 10.1186/1475-2859-12-85.

13.

Development of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrate.

Vilas-Boas V, Silva R, Palmeira A, Sousa E, Ferreira LM, Branco PS, Carvalho F, Bastos Mde L, RemiĆ£o F.

PLoS One. 2013 Aug 26;8(8):e74425. doi: 10.1371/journal.pone.0074425. eCollection 2013.

14.

Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: a prospective cohort analysis.

Chu R, Mills EJ, Beyene J, Pullenayegum E, Bakanda C, Nachega JB, Devereaux PJ, Thabane L.

AIDS Res Ther. 2013 Jul 13;10(1):19. doi: 10.1186/1742-6405-10-19.

15.

Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.

Gupta-Wright A, Wood R, Bekker LG, Lawn SD.

J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):261-70. doi: 10.1097/QAI.0b013e3182a23e9a.

16.

Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study.

Hassen Ali A, Belachew T, Yami A, Ayen WY.

PLoS One. 2013 May 16;8(5):e64622. doi: 10.1371/journal.pone.0064622. Print 2013.

17.

Drug-resistant tuberculosis treatment complicated by antiretroviral resistance in HIV coinfected patients: a report of six cases in Lesotho.

Satti H, McLaughlin MM, Seung KJ.

Am J Trop Med Hyg. 2013 Jul;89(1):174-7. doi: 10.4269/ajtmh.13-0046. Epub 2013 May 13.

18.

Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.

Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO.

Antimicrob Agents Chemother. 2013 Jun;57(6):2780-7. doi: 10.1128/AAC.00191-13. Epub 2013 Apr 9.

19.

Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings.

Peter JG, Theron G, Singh N, Singh A, Dheda K.

Eur Respir J. 2014 Jan;43(1):185-94. doi: 10.1183/09031936.00198012. Epub 2013 Mar 21.

20.

Complications of antiretroviral therapy initiation in hospitalised patients with HIV-associated tuberculosis.

van der Plas H, Meintjes G, Schutz C, Goliath R, Myer L, Baatjie D, Wilkinson RJ, Maartens G, Mendelson M.

PLoS One. 2013;8(2):e54145. doi: 10.1371/journal.pone.0054145. Epub 2013 Feb 8.

Supplemental Content

Support Center